Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.6.1759PMID 11251007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.

  2000cited by this paper
• Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

  1999cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference

  1998cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).

  1998cited by this paper
• Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.

  1998cited by this paper
• Proposal for classifying the acute emetogenicity of cancer chemotherapy.

  1997cited by this paper
• Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

  1997cited by this paper
• The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.

  1997cited by this paper
• Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

  1996cited by this paper
• On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

  1996cited by this paper
• GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.

  1996cited by this paper
• Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.

  1996cited by this paper
• Management of cisplatin-induced delayed emesis.

  1996cited by this paper
• 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.

  1996cited by this paper
• Quality of life studies in chemotherapy-induced emesis.

  1996cited by this paper
• Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.

  1996cited by this paper
• Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.

  1995cited by this paper
• A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.

  1994cited by this paper
• Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.

  1994cited by this paper
• Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study

  1994cited by this paper
• Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.

  1993cited by this paper
• Neurotransmitter functions of mammalian tachykinins.

  1993cited by this paper
• Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH).

  1992cited by this paper
• Phase II trials of ondansetron with high-dose cisplatin.

  1992cited by this paper
• Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

  1991cited by this paper
• Controlling emesis in patients receiving cancer chemotherapy.

  1991cited by this paper
• Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

  1991cited by this paper
• Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.

  1990cited by this paper
• Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

  1990cited by this paper
• Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

  1989cited by this paper
• Controlling emesis in patients receiving cancer chemotherapy.

  1988cited by this paper
• The management of chemotherapy-induced nausea and vomiting.

  1987cited by this paper
• Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

  1985cited by this paper
• Neuropharmacology of Chemotherapy-induced Emesis

  1983cited by this paper
• Emesis as a critical problem in chemotherapy.

  1981cited by this paper
• Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

  1981cited by this paper

• Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer.

  2026cites this paper
• Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.

  2023cites this paper
• Emetogenicity of Chemotherapy Regimens and Recommended Prophylaxis: A Review of MASCC/ESMO Guidelines

  2022cites this paper
• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

  2021cites this paper
• Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future

  2021cites this paper
• Application of Central Composite Design for screening and Optimization of HPTLC method for simultaneous quantitation of Aprepitant, Dexamethasone and Ondansetron in their synthetic mixtures

  2021cites this paper
• Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes

  2021cites this paper
• ED Visits for Emesis following Chemotherapy: Guideline Non-adherence, OP-35, and a Path Back to the Future.

  2021cites this paper
• Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting

  2020cites this paper
• Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

  2020cites this paper
• Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

  2020cites this paper
• Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

  2020cites this paper
• Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

  2020cites this paper
• USEFULNESS OF APREPITANT OVER CONVENTIONAL ANTIEMETIC IN CISPLATIN INDUCED VOMITING –RETROSPECTIVE SINGLE INSTITUTION EXPERIENCE IN TERTIARY CARE CANCER CENTRE

  2020cites this paper
• Evaluation of aprepitant and fosaprepitant in pediatric patients

  2019cites this paper
• Chemotherapy-Induced Nausea/Vomiting (CINV)

  2019cites this paper
• Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial

  2019cites this paper
• Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

  2019cites this paper
• Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study

  2017cites this paper
• Chemotherapy Induced Nausea and Vomiting: Fear Makes the Wolf Bigger than He is

  2017cites this paper
• Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials.

  2016cites this paper
• Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)

  2016cites this paper
• Programmed cell death and clearance of cell corpses in Caenorhabditis elegans

  2016cites this paper
• Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

  2016cites this paper
• An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects.

  2016cites this paper
• Efficacy and Safety of Neurokinin-1 Receptor

  2016cites this paper
• Roles of Substance P in Gastrointestinal Functions and Neuroimmune Interactions

  2016cites this paper
• Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison

  2016cites this paper
• Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

  2016cites this paper
• Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

  2016cites this paper
• The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients

  2016cites this paper
• Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea

  2015cites this paper
• Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy

  2015cites this paper
• A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies

  2015cites this paper
• State of the Art Antiemetic Therapy for Cancer Patients

  2015cites this paper
• Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy.

  2015cites this paper
• Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

  2015cites this paper
• Trójlekowy schemat leczenia: aprepitant, palonosetron i deksametazon w zapobieganiu nudnościom i wymiotom po chemioterapii BEAM z następowym przeszczepieniem autologicznych komórek krwiotwórczych

  2015cites this paper
• Anticipatory nausea in animal models: a review of potential novel therapeutic treatments

  2014cites this paper
• Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails

  2014cites this paper
• Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)

  2014cites this paper
• Prevention of Chemotherapy-Induced Nausea and Vomiting by Olanzapine in Japanese Female Patients with Early Breast Cancer who had Poor Control with the Standard Antiemetic Regimen

  2014cites this paper
• No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion

  2014cites this paper
• The medical implications of gastrointestinal vagal afferent pathways in nausea and vomiting.

  2014cites this paper
• Novel continuous flow technology for the development of a nanostructured aprepitant formulation with improved pharmacokinetic properties.

  2014cites this paper
• Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

  2014cites this paper
• Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting resistant to standard antiemetic treatment for highly emetogenic chemotherapy

  2013cites this paper
• The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting

  2013cites this paper
• An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting

  2013cites this paper
• Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

  2013cites this paper
• 術後病期II～IIIA期非小細胞肺癌に対する分割投与法によるシスプラチン，ビノレルビン併用術後補助化学療法の忍容性と有効性に関する後方視的検討

  2013cites this paper
• Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties

  2013cites this paper
• The Impact of Prolonged Anandamide Availability by Anandamide Transport Inhibition on Nausea-Induced Behaviour in Rats and Vomiting in Shrews (Suncus murinus)

  2013cites this paper
• NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.

  2013cites this paper
• 8. Overlapping Phenotypes

  2013cites this paper
• Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting

  2012cites this paper
• An overview of nausea/vomiting in palliative medicine.

  2012cites this paper
• Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier on

  2012cites this paper
• Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting

  2012cites this paper
• Acupuncture and Moxibustion as an Evidence-based Therapy for Cancer

  2012cites this paper
• Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.

  2012influential citation
• Aprepitant

  2012cites this paper
• Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis

  2012cites this paper
• Aprepitant

  2012cites this paper
• Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients

  2012cites this paper
• Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

  2012cites this paper
• Chapter 18 – Nausea and Vomiting

  2012cites this paper
• Acupuncture and Moxibustion for Side Effects of Chemotherapy in Cancer Patients

  2012cites this paper
• Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.

  2012cites this paper
• Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting

  2012influential citation
• Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation.

  2011cites this paper
• Management of Nausea and Vomiting in Cancer Patients

  2011cites this paper
• Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

  2011cites this paper
• Behavioral Patterns Associated with Chemotherapy-Induced Emesis: A Potential Signature for Nausea in Musk Shrews

  2011cites this paper
• A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.

  2011cites this paper
• Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

  2011cites this paper
• Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting

  2011cites this paper
• Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.

  2010cites this paper
• Leitliniengerechte Therapie von Übelkeit und Erbrechen

  2010cites this paper
• [Chemotherapy induced emesis: pathophysiology and prevention].

  2010cites this paper
• Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults

  2010cites this paper
• Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

  2010cites this paper
• Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.

  2010cites this paper
• Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.

  2010cites this paper
• Aprepitant (Emend): A NK1 Receptor Antagonist for the Treatment of Postchemotherapy Emesis

  2010cites this paper
• Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice

  2010cites this paper
• Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

  2010cites this paper
• [Treatment of tumor therapy-induced nausea and vomiting].

  2009cites this paper
• Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.

  2009cites this paper
• Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer

  2009cites this paper
• Antiemetic control: toward a new standard of care for emetogenic chemotherapy

  2009influential citation
• A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew.

  2009cites this paper
• Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

  2009cites this paper
• [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].

  2009cites this paper
• Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

  2009cites this paper
• Symptom Management in Children with Cancer

  2009cites this paper
• Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?

  2008cites this paper
• Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.

  2008cites this paper
• Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

  2008cites this paper
• Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting

  2008cites this paper